Novopyxis
Madhavi Gavini has extensive experience in the field of biophysics and therapeutic development. Madhavi is the CEO and Founder of Droplette since 2017. Prior to this, they worked at Novopyxis from 2013-2017 as the President and Cofounder, where they developed a patent-pending portfolio of novel therapeutics and drug delivery systems. Madhavi focused on engineering transdermal delivery devices for cosmetics applications and rare diseases. Before that, Madhavi was a Cofounder at Integrative Enzymatics from 2011-2013. In 2010, they worked as a Visiting Graduate Student at the Computational Biophysics Group, studying the monomeric structure of amyloid beta protein. Overall, Madhavi Gavini's work experience showcases their expertise in leadership, entrepreneurship, and scientific research.
Madhavi Gavini's education history includes studying Mathematics at the Massachusetts Institute of Technology. However, no information is provided regarding the specific years or degree obtained. Additionally, Madhavi Gavini pursued a field of study in Neuroscience at The Johns Hopkins University. Again, specific details such as start and end years, as well as degree attainment, are not given.
This person is not in the org chart
This person is not in any teams
Novopyxis
Novopyxis is an award-winning biotechnology company dedicated to the development of therapeutics and medical devices. Novopyxis’ flagship drug was developed using in-house proprietary mathematical algorithms and has been validated across several different in vitro, ex vivo, and in vivo models. It activates a key anti-inflammatory receptor calledthe AT2R and is both cardioprotective and neuroprotective. Their therapeutic was recently awarded an orphan designation for "Pediatric Cardiomyopathy" from the FDA. Droplette was recently spun out from Novopyxis (www.droplette.io) and is focused on the development of a patented medical device for the delivery of large molecules, DNA/RNA, and proteins deep through skin, tissue, and cells. They are currently partnered with Leo Pharma for the development of their device for medical dermatology applications and have won several awards including the 2015 Graduate of MassCONNECT program via MassBio, 2015 Amgen Golden Ticket Winner, 2014 Mass Challenge Finalist, Winner of 2014 CASIS-Boeing Prize for Technology in Space, and Second place winner in 2015 M2D2 New Ventures Competition